Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01609621 · ClinicalTrials.gov registry record
Tibiopedal Access for Crossing of Infrainguinal Artery Occlusions
A clinical trial, sponsored by Cook Group Incorporated.
- Completed
- Registry status
- 199
- Enrollment target
NCT01609621: Completed study, sponsored by Cook Group Incorporated.
NCT01609621 is a clinical trial that has completed, run by Cook Group Incorporated. The registered enrollment target is 199 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01609621 has completed, sponsored by Cook Group Incorporated.
- COMPLETED
- Registry status
- 199 participants
- Enrollment target
Study Summary
The objective of this prospective, non-randomized, multicenter, post-market, observational study is to compile clinical data on percutaneous techniques used to obtain tibiopedal access and to cross infrainguinal arterial occlusions.
Interventions
- DEVICE Retrograde tibiopedal arterial access
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 199 participants |
| Start Date | 2012-05 |
| Est. Completion | 2013-08 |
What the finished NCT01609621 record still lists
NCT01609621 is an observational study that tracks outcomes without assigning an intervention. The registered 199 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Retrograde tibiopedal arterial access is the first listed.
NCT01609621 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01609621 about?
NCT01609621 is a clinical study titled "Tibiopedal Access for Crossing of Infrainguinal Artery Occlusions". The objective of this prospective, non-randomized, multicenter, post-market, observational study is to compile clinical data on percutaneous techniques used to obtain tibiopedal access and to cross infrainguinal arterial occlusions.
What is the current status of trial NCT01609621?
This trial is currently completed. The enrollment target is 199 participants. The study started on 2012-05. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01609621?
The interventions under investigation include: Retrograde tibiopedal arterial access (DEVICE).
Who is sponsoring clinical trial NCT01609621?
This trial is sponsored by Cook Group Incorporated, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04312126 · 199 participants
The Beneficial Effects of Naps on Motor Learning
- NCT04951622 · 199 participants · Phase 3
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- NCT06474533 · 199 participants
Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia